The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Cota Healthcare
Stock and Other Ownership Interests - Cota Healthcare
Real-world outcomes of treatment with immune checkpoint inhibitors in unique patient cohorts: Elderly, non-caucasian race, poor performance status, obese, chronic viral infections, and autoimmune diseases.
 
Neil J. Shah
Consulting or Advisory Role - Merck Sharp & Dohme Corp.
 
Shuo Wang
No Relationships to Disclose
 
Aquino Williams
No Relationships to Disclose
 
Melinda Weber
Employment - Bristol Myers Squibb Foundation
Honoraria - Bristol Myers Squibb Foundation
Speakers' Bureau - Bristol Myers Squibb Foundation
 
Brittany Sinclaire
No Relationships to Disclose
 
Elli Gourna Paleoudis
No Relationships to Disclose
 
Adil Alaoui
Leadership - eKare
Stock and Other Ownership Interests - eKare Inc. eHMISA
 
Shaked lev-Ari
No Relationships to Disclose
 
Shari Adams
No Relationships to Disclose
 
Jordan Kaufman
No Relationships to Disclose
 
Sahil B. Parikh
No Relationships to Disclose
 
Emily Tonti
No Relationships to Disclose
 
Eric Muller
No Relationships to Disclose
 
Michael T Serzan
No Relationships to Disclose
 
Divya Cheruku
No Relationships to Disclose
 
Jaeil Ahn
No Relationships to Disclose
 
Andrew Pecora
No Relationships to Disclose
 
Andrew Ip
Stock and Other Ownership Interests - Merck (I)
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Adagene; Agenus; Arrowhead Pharmaceuticals; AstraZeneca; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; Idera; Immunocore; Iovance Biotherapeutics; Leads Biolabs; Merck; Neoleukin Therapeutics; Novartis; PACT Pharma; Pfizer; Pneuma Respiratory; Pyxis; Scholar Rock; Seagen; Surface Oncology; Third Rock Ventures; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst)